528593-71-7

Basic information

• Product Name: 5-[(1-Indolyl)Methyl]-3-Methylisoxazole
• Synonyms: 5-[(1-Indolyl)Methyl]-3-Methylisoxazole;1-[(3-methyl-5-isoxazolyl)methyl]-1H-Indole;5-((1H-Indol-1-yl)methyl)-3-methylisoxazole
• CAS NO: 528593-71-7
• Molecular Formula: C₁₃H₁₂N₂O
• Molecular Weight: 212.24718
• Mol File: 528593-71-7.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-[(1-Indolyl)Methyl]-3-Methylisoxazole(CAS DataBase Reference)
• NIST Chemistry Reference: 5-[(1-Indolyl)Methyl]-3-Methylisoxazole(528593-71-7)
• EPA Substance Registry System: 5-[(1-Indolyl)Methyl]-3-Methylisoxazole(528593-71-7)

Safety Data

• Hazardous Substances Data: 528593-71-7(Hazardous Substances Data)

Usage

General Description

5-[(1-Indolyl)Methyl]-3-Methylisoxazole is an organic compound with the chemical formula C15H14N2O. It is a heterocyclic compound that contains both an isoxazole ring and an indole moiety. 5-[(1-Indolyl)Methyl]-3-Methylisoxazole has been found to possess various biological activities, including potential anti-inflammatory and antitumor properties. It has also been studied for its potential role in treating neurological disorders. The compound's structure and properties make it of interest for further research and potential development as a pharmaceutical agent.

Upstream product

• 120-72-9 indole 
• 40340-41-8 5-chloromethyl-3-methylisoxazole 

Relevant articles and documents

Synthesis and biological evaluation of N-heterocyclic indolyl glyoxylamides as orally active anticancer agents

A series of N-heterocyclic indolyl glyoxylamides were synthesized and evaluated for in vitro and in vivo anticancer activities. They exhibited a broad spectrum of anticancer activity not only in murine leukemic cancer cells but also in human gastric, breast, and uterus cancer cells as well as their multidrug resistant sublines with a wide range of IC50 values. They also induced apoptosis and caused DNA fragmentation in human gastric cancer cells. Among the compounds studied, 7 showed the most potent activity of growth inhibition (IC50 17-1711 nM) in several human cancer cells. Given orally, compounds 7 and 13 dose-dependently prolonged the survival of animals inoculated with P388 leukemic cancer cells. N-Heterocyclic indolyl glyoxylamides may be useful as orally active chemotherapeutic agents against cancer and refractory cancerous diseases of multidrug resistance phenotype.